BioAge Labs (BIOA) – Investment Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of BioAge Labs (NASDAQ: BIOA) in the last few weeks:

• 8/3/2026 – BioAge Labs had its “buy” rating reaffirmed by BTIG Research. They now have a $40.00 price target on the stock.
• 7/31/2026 – BioAge Labs had its “buy” rating reaffirmed by Roth Capital. They now have a $25.00 price target on the stock.
• 7/31/2026 – BioAge Labs was given a new $21.00 price target by Jefferies Financial Group Inc..
• 7/31/2026 – BioAge Labs had its price target lowered by Needham & Company LLC from $50.00 to $35.00. They now have a “buy” rating on the stock.
• 7/21/2026 – BioAge Labs had its “sell (d-)” rating reaffirmed by Weiss Ratings.

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.

See Also

• Five stocks we like better than BioAge Labs
• Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
• Legacy Jet Builders Stall While Embraer Accelerates to New Highs
• Intel’s Rally Gave It a $20 Billion Opportunity and Now Comes the Hard Part
• Visa’s AI Opportunity Is Hiding in Every Transaction